Excellence is just the beginning.


French German Italian Portuguese Russian

Melanoma Surveillance Clinic — Clinical Trials

Treatment Study For Patients With Advanced BRAFV600 Mutant Melanoma

Dabrafenib + trametinib followed by ipilimumab + nivolumab at progression or ipilimumab + nivolumab followed by dabrrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma.

Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma

Nivolumab plus ipilimumab plus sargramostin versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma.